Drug Profile
Product B
Latest Information Update: 22 Feb 2023
Price :
$50
*
At a glance
- Originator Sylentis
- Class Anti-inflammatories; Gene therapies; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Arthritis; Crohn's disease; Ulcerative colitis
Most Recent Events
- 22 Feb 2023 Discontinued - Preclinical for Crohn's disease in Spain (unspecified route)
- 22 Feb 2023 Discontinued for Arthritis in Spain (unspecified route)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Crohn's-disease in Spain